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Objectives The goal of this study was to assess the risk associated with double antiplatelet therapy (DAT) discontinuation,
and specifically, temporary discontinuation, during the first year after drug-eluting stent (DES) implantation.
Background Doubts remain about the risk of temporary DAT discontinuation within 1 year after DES implantation.
Methods A total of 1,622 consecutive patients undergoing DES implantation at 29 hospitals were followed up at 3, 6, 9,
and 12 months to record the 1-year antiplatelet therapy discontinuation (ATD) rate, the number of days without
DAT, and the rate of 1-year major cardiac events. Cox regression was used to analyze the association between
ATD considered as a time-dependent covariate and 1-year cardiac events.
Results One hundred seventy-two (10.6%) patients interrupted at least 1 antiplatelet drug during the first year after DES im-
plantation, although only 1 during the first month. Most (n  111, 64.5%) interrupted DAT temporarily (median: 7
days; range: 5 to 8.5): 79 clopidogrel (31 temporarily), 38 aspirin (27 temporarily), and 55 both drugs (53 temporar-
ily). Discontinuation was followed by acute coronary syndrome in 7 (4.1%; 95% confidence interval [CI]: 1.7 to 8.2), a
similar rate of major cardiac events to that in patients without ATD (n  80; 5.5%; 95% CI: 4.4 to 6.8; p  0.23). ATD
was not independently associated with 1-year major cardiac events (hazard ratio: 1.32 [95% CI: 0.56 to 3.12]).
Conclusions ATD within the first year and beyond the first month after DES is not exceptional, is usually temporary, and does
not appear to have a large impact on risk. (J Am Coll Cardiol 2012;60:1333–9) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.057Premature and permanent thienopyridine discontinuation
after drug-eluting stent (DES) implantation conveys a risk
for stent thrombosis (1–4), probably on the basis of
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Discontinuing Antiplatelet Therapy and Drug-Eluting Stents October 9, 2012:1333–9Although the risk is highest dur-
ing the first month after DES
implantation and still high within
the first 6 months (4,6), a safe time
period for antiplatelet therapy dis-
continuation (ATD) has not yet
been defined (7,8). Furthermore,
information is scanty about the
risk of temporary ATD during
the first year that may occur in
different scenarios, such as life-
threatening hemorrhage, surgical
intervention, errors in medical
prescription, or lack of adherence. However, the current
evidence has been interpreted as implying that any inter-
ruption can be dangerous (6,9).
The ACDC (Adherence to Treatment of Coronary Patients
After a Catheterization With DES Implantation) is a prospec-
tive cohort study addressing the background, incidence, poten-
tial predictors, and safety of ATD during the first year after
DES implantation (10). It showed that over 14% of patients
who received DES interrupted at least 1 antiplatelet drug
during the first year after DES implantation, in most cases
clopidogrel, usually temporarily, and that discontinuation was
most often based on patient decision or medical decisions not
associated with major bleeding events or major surgical
procedures.
In the present paper, we assess the risk associated with ATD
in the ACDC cohort, and specifically, temporary discontinu-
ation, during the first year of DES implantation in terms of
cardiac mortality or acute coronary syndrome (ACS).
Methods
Study design and participants. Methods of the ACDC
study have been described elsewhere (10). All patients receiving
at least 1 DES between January 28, 2008, and April 28, 2008,
were recruited by clinical investigators in 29 participating
hospitals from Spain. Local investigators were specifically
trained and actively participated in the draft of the study
protocol.
Study variables included data related to coronary angiog-
raphy, cardiovascular risk factors, cardiovascular history,
complications during admission, and medications at dis-
charge. In addition, psychosocial variables and several hos-
pital characteristics were recorded.
A quality control was performed to ensure consecutive
inclusion and quality of data collection in 28 of 29 centers. This
quality control led to include retrospectively 75 patients who
had been missed by local investigators and to review all the data
entered in 5 centers where more than 5 errors/patients were
detected.
Follow-up. All patients who signed informed consent were
interviewed by phone by trained researchers at 3, 6, 9, and
12 months using a standardized questionnaire to determine:
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
ATD  antiplatelet therapy
discontinuation
CI  confidence interval
DAT  double antiplatelet
therapy
DES  drug-eluting stent(s)
HR  hazard ratio1) vital status; 2) current medications (patients were asked tocollect all their current medications and to read out every
brand name); 3) medications temporally or permanently
interrupted since the previous phone call; 4) reason and
duration of discontinuation; and 5) hospital readmissions.
For patients who died, a close relative was interviewed. In
case of readmission, clinical records were reviewed at the
corresponding center and centrally checked by the main
investigator team to establish the reason for readmission and
medications during hospitalization and at discharge.
From the phone interviews and the review of clinical
records, the following data were assessed for each patient:
the approximate date of ATD, the antiplatelet drug that had
been interrupted (clopidogrel, aspirin, or both), and in the
case of resuming the antiplatelet drug, the date of resump-
tion. Thus, the approximate number of days of discontinu-
ation could be determined in each patient.
The main outcomes of interest were ACS and cardiac death.
Both were identified from clinical records by the main inves-
tigator team, who was blind to the DAT status at the time of
endpoint adjudication. ACS required an increase of cardiac
necrosis biomarkers above the upper limit for each local
laboratory plus either suggestive symptoms or electrocardio-
gram changes. Cardiac death was considered in cases of ACS,
congestive heart failure, or unexpected death not clearly second-
ary to a noncardiac cause. The events were adjudicated by the
main coordinator team with use of the original source documents.
Statistical analysis. Descriptive data are presented as mean
SD or proportions for individual characteristics.
To explore the association between ATD and 1-year cardiac
mortality or ACS, we used survival analysis, patients being
censored at the time of the first of the 2 events. Other causes
of censoring were death from noncardiovascular causes, bypass
surgery, and loss to follow-up. We employed extended Cox
regression modeling, introducing the covariate ATD as time
dependent. We introduced the variable ATD using a step
function that equals 0 all the time the individual is taking
clopidogrel and aspirin, and equals 1 when the individual is not
taking clopidogrel and aspirin. We also explored the specific
effect of interrupting aspirin or clopidogrel, or both, assigning
a different value to each category. Additionally, we explored the
specific risk of temporary ATD (i.e., the interruption of
antiplatelet therapy and subsequent resumption without the
occurrence of any new revascularization or cardiovascular
event) by censoring, at the time of ATD, patients who
interrupted any drug without resumption.
We first estimated the crude effect of ATD, including it
in the model as a single variable (i.e., crude estimate). To
estimate the adjusted effect of ATD on cardiac death or
ACS, we considered those variables that may potentially be
common causes of exposure (i.e., ATD) and outcome (11)
as candidate confounders. We considered factors related
with the global patient risk, factors related with the severity
and natural history of the coronary disease, and factors
related with the hospital where the patient underwent the
procedure (i.e., teaching hospital and mean number of
patients receiving stents in 1 year). All these factors were
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the effect of the exposure 10%. Proportional hazards
assumption was tested for each variable by plots (log (time)
versus log [log (survival)] stratified by the variable).
Several patients died of cardiac causes during the follow-
up. In this case, although researchers interviewed their
relatives, the possibility of information bias concerning the
discontinuation of AT before dying was plausible. Thus, we
performed a simulation analysis as sensitivity analysis. The
objective was to quantify the impact of a potential informa-
tion bias. In cases of death from cardiac causes, we simu-
lated different rates of ATD preceding death: 0%, 10%,
25%, 50%, and 100%. Patients who died of cardiac causes
were randomly selected for ATD, assuming a Bernoulli
distribution. The interval between ATD and death was
simulated to be 7 and 15 days. The interval of 7 days was
chosen as this was the actual median number of days
without DAT in those patients with temporary discontin-
Figure 1 Outcome Event Incidence Along Follow-Up and Its Re
Most cases of outcome events were not preceded by antiplatelet therapy disconti
on the top indicate the number of patients at risk at the beginning of each period
have resumed the therapy during the following period. ACS  acute coronary synd
posite endpoint; DAT  double antiplatelet therapy.
Features of ATD in 7 Patients With Subsequent EventsTable 1 Features of ATD in 7 Patients With Subsequent Events
Type of Drug
Interrupted
Days to
ATD
Treatment Resumed
Before Event
Patient #1 Both 191 No
Patient #2 Both 90 No
Patient #3 Clopidogrel 84 Yes
Patient #4 Clopidogrel 60 No
Patient #5 Aspirin 266 Yes
Patient #6 Both 180 No
Patient #7 Aspirin 94 NoACS  acute coronary syndrome; ATD  antiplatelet therapy discontinuation; DAT  double antiplateletuation. The previous Cox model was employed to include
the variable ATD, again as a time-dependent covariate, but
assuming the new ATD distribution. We made 15 itera-
tions to estimate the risk of ATD.
Results
Twenty of 1,985 patients included in the ACDC study died
during admission. Thus, there were 1,965 candidates to
follow-up. At least 1 time-point follow-up (3, 6, 9, or 12
months) could be assessed in 1,622 (82.5%). In 1,536
patients, follow-up could be achieved for the 4 time points.
In the rest, only 2 or 3 follow-up time points were available.
Figure 1 shows the cumulative incidence of the endpoint
cardiac mortality or ACS along the 4 time-point study
period and its relationship with previous ATD. Eighty-
seven of 1,622 patients (5.4%; 95% confidence interval [CI]:
4.3 to 6.6) had a major cardiac event during the first year
ship With ATD
(ATD). *Censored for other reason different from outcome events. The boxes
that a patient may have interrupted antiplatelet therapy at one period and may
); ATD  antiplatelet therapy discontinuation; CD  cardiac death; CEP  com-
of Event
Days From ATD
to Event
Days From ATD
Resumption to Event
Total Days
Without DAT
CS 14 NA 14
CS 3 NA 3
CS 246 239 7
CS 328 NA 328
CS 14 4 10
CS 193 NA 193
CS 222 NA 222lation
nuation
. Note
rome(sType
A
A
A
A
A
A
Atherapy; DES  drug-eluting stent(s); NA  not applicable.
t
i
1
3
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15.9) was a history of ATD recorded. These 7 patients had
ACS, and there was important variability concerning the
drug interrupted, the moment and duration of interruption,
and the time from ATD to event (Table 1). The rate of
ATD in patients with events was similar to that among the
1,535 patients without events or who had been censored
before the end of follow-up (n  165, 10.7%; 95% CI: 9.2
o 12.4; p  0.23). Overall, 172 (10.6%) patients had
nterrupted at least 1 antiplatelet drug, most of them (n 
11, 64.5%) temporarily: 79 clopidogrel (31 temporarily),
Baseline Characteristics of the Study Population According to ATDTable 2 Baseline Characteristics of the Study Population Acco
No ATD (n  1,45
Valid, n
Demographic and cardiovascular risk factors
Age, yrs 1,435 64
Women 1,450 317 (2
Active smoker 1,450 320 (2
Hypercholesterolemia 1,450 881 (6
Hypertension 1,450 972 (6
Diabetes mellitus 1,450 529 (3
Cardiovascular history
Peripheral artery disease 1,450 169 (1
Stroke 1,450 71 (4
Heart failure 1,450 85 (5
Pacemaker 1,450 16 (1
Valvular prosthesis 1,450 4 (0
Atrial fibrillation 1,450 58 (4
Previous AMI 1,450 423 (2
Previous CABG 1,450 120 (8
Previous PTCA 1,450 405 (2
Other conditions
Chronic obstructive pulmonary disease 1,450 136 (9
Chronic renal impairment 1,450 90 (6
Previous major hemorrhage 1,450 26 (1
Previous major surgery 1,450 417 (2
Chronic hepatic disease 1,450 14 (1
Oncologic disease 1,450 26 (1
Surgery scheduled for the following year 1,450 39 (2
Long-term AT before admission 1,450 754 (5
Long-term AC before admission 1,450 57 (3
Psychosocial characteristics
Immigrant 1,450 43 (3
Professional situation
Employed 1,431 490 (3
Retired 1,431 782 (5
Unemployed 1,431 40 (2
Other situation 1,431 119 (8
Education level
Low education level 1,429 399 (2
Medium education level 1,429 632 (4
High education level 1,429 398 (2
PHQ9
Low/medium disorder 1,431 1,250 (8
Moderate to severe disorder 1,431 181 (18 aspirin (27 temporarily), and 55 both drugs (53 tempo-rarily). The median number of days without DAT in those
who resumed was 7 (interquartile range: 5 to 8.5). The rate of
ATD varied slightly across the 4 study intervals: 2.16%, 1.7%,
3.6%, and 3.6%, respectively. Only 1 patient interrupted DAT
during the first month after DES implantation. It was to
prevent hemorrhagic risk during an admission for endocarditis,
and the patient died of sepsis several days later.
Table 2 shows the baseline characteristics of the study
population according to the ATD status. Patients who
interrupted DAT had a lower rate of prior coronary angio-
plasty and a higher rate of comorbidities such as chronic
to ATD
ATD (n  172) Global (n  1,622)
p ValueValid, n Valid, n
172 65 12 1,607 64.1 11 0.19
172 33 (19.2%) 1,622 350 (21.6%) 0.49
172 39 (22.7%) 1,622 359 (22.1%) 0.85
172 104 (60.5%) 1,622 985 (60.7%) 0.93
172 113 (65.7%) 1,622 1,085 (66.9%) 0.73
172 59 (34.3%) 1,622 588 (36.3%) 0.61
172 27 (15.7%) 1,622 196 (12.1%) 0.14
172 10 (5.8%) 1,622 81 (5%) 0.58
172 12 (7%) 1,622 97 (6%) 0.50
172 2 (1.2%) 1,622 18 (1.1%) 1.00
172 2 (1.2%) 1,622 6 (0.4%) 0.13
172 11 (6.4%) 1,622 69 (4.3%) 0.16
172 43 (25%) 1,622 466 (28.7%) 0.28
172 11 (6.4%) 1,622 131 (8.1%) 0.46
172 35 (20.3%) 1,622 440 (27.1%) 0.04
172 25 (14.5%) 1,622 161 (9.9%) 0.04
172 21 (12.2%) 1,622 111 (6.8%) 0.01
172 9 (5.2%) 1,622 35 (2.2%) 0.01
172 56 (32.6%) 1,622 473 (29.2%) 0.33
172 4 (2.3%) 1,622 18 (1.1%) 0.11
172 3 (1.7%) 1,622 29 (1.8%) 1.00
172 5 (2.9%) 1,622 44 (2.7%) 0.80
172 88 (51.2%) 1,622 842 (51.9%) 0.87
172 8 (4.7%) 1,622 65 (4%) 0.68
172 7 (4.1%) 1,622 50 (3.1%) 0.48
0.6
168 51 (30.4%) 1,599 541 (33.8%)
168 100 (59.5%) 1,599 882 (55.2%)
168 3 (1.8%) 1,599 43 (2.7%)
168 14 (8.3%) 1,599 133 (8.3%)
167 50 (29.9%) 1,596 449 (28.1%) 0.76
167 69 (41.3%) 1,596 701 (43.9%)
167 48 (28.7%) 1,596 446 (27.9%)
167 147 (88%) 1,598 1,397 (87.4%) 0.90
167 20 (12%) 1,598 201 (12.6%)
Continued on next pagerding
0)
11
1.9%)
2.1%)
0.8%)
7%)
6.5%)
1.7%)
.9%)
.9%)
.1%)
.3%)
%)
9.2%)
.3%)
7.9%)
.4%)
.2%)
.8%)
8.8%)
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.8%)
.7%)
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differences between both groups concerning psychosocial
characteristics. Finally, patients who interrupted DAT were
attended less often in more active centers (i.e., with higher
rates of patients receiving stents in 1 year).
Risk of ATD during the first year after DES implantation.
The unadjusted global risk (hazard ratio [HR]) of cardiac
death or ACS associated with ATD was 1.93 (95% CI: 0.87
to 4.28; p  0.1): 1.95 (95% CI: 0.47 to 7.99; p  0.35) for
solated aspirin discontinuation, 1.34 (95% CI: 0.32 to 5.5;
 0.68) for isolated clopidogrel discontinuation, and 2.71
95% CI: 0.84 to 8.72) for DAT discontinuation. When
djusting for potential confounders, the association re-
ained nonsignificant (Table 3). The same was true when
ssessing the risk of the isolated temporary ATD by
ContinuedTable 2 Continued
No ATD (n  1,45
Valid, n
Admission features
Acute coronary syndrome (admission diagnosis) 1,450 840 (5
Worst Killip class III–IV during admission 1,450 37 (2
Heart failure during admission 1,450 85 (5
Major hemorrhage during admission 1,450 7 (0
Ejection fraction below 45% at discharge (n  1,203) 1,072 167 (1
AC therapy prescribed at discharge 1,446 32 (2
Off-label indications of DES 1,439 937 (6
Type of DES
Sirolimus 1,450 221 (1
Everolimus 1,450 500 (3
Paclitaxel 1,450 560 (3
Zotarolimus 1,450 234 (1
Patient included in clinical trial 1,445 183 (1
Hospital characteristics
University hospital 1,450 1,249 (8
Private funding 1,450 181 (1
Mean number of patients attended
500 patients/yr 1,450 453 (3
500–1,000 patients/yr 1,450 523 (3
1,000 patients/yr 1,450 474 (3
Values are mean  SD or n (%). *10 years per unit of risk increase; †100 beds per unit of risk
AC anticoagulant; AMI acute myocardial infarction; AT antiplatelet therapy; CABG coro
coronary angioplasty; other abbreviations as in Table 1.
Adjusted Risk of Major Cardiac Eventssociated With DAT DiscontinuationDuring the First Ye r After DES Implantation
Table 3
Adjusted Ri k of Major Cardiac Event
Associated With DAT Discontinuation
During the First Year After DES Implantation
HR 95% CI p Value
Antiplatelet therapy discontinuation 1.32 0.56–3.12 0.526
Aspirin 1.33 0.32–5.49 0.696
Clopidogrel 1.29 0.31–5.34 0.725
Both 1.34 0.32–5.63 0.685
Age (each 10 yrs) 1.37 1.10–1.70 0.005
Chronic obstructive pulmonary disease 1.81 1.04–3.14 0.035
Chronic renal impairment 2.88 1.66–4.99 0.001
Worst Killip class III–IV during admission 1.65 1.04–2.61 0.032
Off-label indications of DES 1.85 1.10–3.09 0.020CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.censoring the patients who did not resume DAT at the time
of ATD: HR: 0.86 (95% CI: 0.21 to 3.6; p  0.83).
SIMULATION STUDY. Figure 2 shows the HR and 95% CI of
cardiac death or ACS when simulating, in those patients
who died of cardiac reasons, a rate of ATD 7 days before
dying of 0%, 10%, 25%, 50%, 75%, and 100%. The risk of
major cardiac events associated with ATD would have been
statistically significant if at least 18.8% of patients who died
had interrupted DAT 7 days before dying (HR: 2.04; 95%
ATD (n  172) Global (n  1,622)
p ValueValid, n Valid, n
172 107 (62.2%) 1,622 947 (58.4%) 0.29
172 9 (5.2%) 1,622 46 (2.8%) 0.05
172 12 (7%) 1,622 97 (6%) 0.50
172 0 (0%) 1,622 7 (0.4%) 1.00
131 25 (19.1%) 1,203 192 (16%) 0.31
171 6 (3.5%) 1,617 38 (2.4%) 0.28
169 81 (47.9%) 1,608 1,018 (63.3%) 0.001
) 172 23 (13.37%) 1,622 244 (15.04%) 0.574
) 172 50 (29.07%) 1,622 550 (33.91%) 0.173
) 172 66 (38.37%) 1,622 626 (38.59%) 1.000
) 172 27 (15.7%) 1,622 261 (16.09%) 1.000
170 22 (12.9%) 1,615 205 (12.7%) 0.90
172 145 (84.3%) 1,622 1,394 (85.9%) 0.49
172 18 (10.5%) 1,622 199 (12.3%) 0.54
0.033
172 60 (34.9%) 1,622 513 (31.6%)
172 73 (42.4%) 1,622 596 (36.7%)
172 39 (22.7%) 1,622 513 (31.6%)
e; ‡100 patients per unit of risk increase; §Cutoff PHQ value  10.
ery bypass grafting; PHQ Patient Health Questionnaire-915; PTCA percutaneous transluminal
Figure 2 Risk of Outcome Event According to Different
Simulated Rates of ATD Before Death
The ordinate expresses the log hazard ratios (HR) and 95% confidence inter-
vals (error bars) of cardiac death or acute coronary syndrome when simulating,
in those patients who died of cardiac causes, a rate of antiplatelet therapy dis-
continuation (ATD) before dying of 0%, 10%, 25%, 50%, 75%, and 100%.0)
7.9%)
.6%)
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have had to misclassify at least 18.8% who died of cardiac
causes concerning ATD (i.e., false negatives) to conclude
that there was not a statistically significant risk of cardiac
events associated with ATD when actually there was.
Similar results were obtained simulating the interruption of
DAT 15 days before dying (data not shown).
Discussion
The ACDC study shows that although ATD during the
first year after DES implantation is not exceptional, in most
instances, it was a temporal interruption, the antiplatelet
medication being resumed in the following days (median: 7
days). Most importantly, it was not necessarily followed by
major cardiovascular events, at least in patients who inter-
rupted DAT later than 1 month after stenting, which was
the most common situation in our population.
Interruption of antiplatelet drugs has been shown to be
deleterious in several contexts (12), particularly DES
thrombosis after clopidogrel discontinuation (1,4,13). How-
ever, the impact of discontinuation is less clear after the
study by Kimura et al. (14), which casts doubts about the
actual role of thienopyridines associated with aspirin for
preventing stent thrombosis. Likewise, in another registry (4),
lopidogrel discontinuation was not associated with stent
hrombosis when it occurred later than 6 months after DES
mplantation. Although our study was not aimed at assessing
tent thrombosis, the tight relationship between stent throm-
osis and cardiac death and ACS (4,15,16) leads to similar
onclusions regarding the risk assessment of ATD.
The absence of risk of major cardiovascular events asso-
iated with ATD found in the present study may be
xplained by several reasons. First, the rate of ATD during
he first month after stenting, the period with the highest
isk for ATD (2,3), was negligible. Second, most patients
iscontinued only clopidogrel or aspirin, and discontinua-
ion was temporary in most, its median duration being 7
ays. This is in agreement with recent studies in which a
isk of stent thrombosis associated with isolated clopidogrel
iscontinuation was not shown (14) or was limited to the
arly period of the treatment (4,17), and where the highest
ate of stent thrombosis was usually detected beyond 1 week
fter discontinuation (4,14). And, third, although in our
tudy the rate of patients undergoing DES implantation in the
ontext of ACS reached 58%, this rate is lower than in other
eries that have recorded devastating consequences of clopi-
ogrel discontinuation (3), which is probably the context in
hich DAT is more advantageous. In fact, a recent study about
lopidogrel discontinuation after ACS showed a higher risk of
eath or nonfatal myocardial infarction in those patients who
efinitely interrupted clopidogrel therapy (18).
Bias may play a role in the results. Specifically, the presence
f information bias concerning antiplatelet use could, if ex-
reme, invalidate the results. This risk is especially high in those
atients who died, and thus the interviewee had to be a relative. bherefore, we simulated that the information obtained from
he relative was wrong in the sense of “favoring” a potential
nderlying relationship between ATD and major cardiac
vents. Considering the most unfavorable scenario of misclas-
ification of ATD in those patients who died from cardiac
auses, at least 18.8% wrong ATD categorizations would have
een needed to falsely conclude an absence of significant risk
ssociated with ATD. Although we believe that such a high
ate of misclassification is unlikely, even in this worst scenario,
he risk of serious events associated with ATD would have ranged
rom an HR of 1.01 to an HR of 4.1, which is a far less
evastating effect than reported in other studies (2,4). The bias of
rong ATD classification in those patients who did not die seems
ess likely. Conversely, it could also be possible that the high rate
f adverse events associated with clopidogrel discontinuation
bserved in other studies (3) was partially due to a bias in the sense
f detecting more ATD in those patients with events.
Studies usually evaluate the status of thienopyridine use at
ertain time intervals (3,4,13), and occasionally, they have
nalyzed it immediately before an event (4,14,15). In the
resent study, we assessed the consequences of the most
ommon situation, that is, the temporal discontinuation of
lopidogrel and/or aspirin for a few days with subsequent
esumption. This has received less attention, or its evaluation
as been less clear, probably because of its complexity. In
ddition to the problems in adherence assessment, there are
ifficulties of definition that hinder comparison or interpreta-
ion in different studies. For instance, in some studies (13),
omplete interruption is defined as any discontinuation lasting
or longer than a given period, not providing further data on its
ctual duration. In fact, most studies lack information about
he temporary or permanent character of discontinuation (18).
Temporary ATD may occur in different scenarios, more
ften in the context of bleeding events or invasive proce-
ures (10). In the present work, we used extended Cox
egression modeling with a time-dependent covariate,
hich permits us to examine the continuous risk of ATD
nd thus the implications of temporary ATD. Our results
uggest that a discontinuation for a few days (median: 7
ays) of ATD after the first month of DES implantation
ay be reasonably safe in terms of major cardiac events.
owever, the absence of a statistically significant association
ay have been because of insufficient power, as convincing
nstances of stent thrombosis shortly after ATD have been
eported. Moreover, it is possible that some of the cardiac
vents observed in the ACDC study, with or without DAT,
ay have been due to stent thrombosis. In any case, our study
uggests that the risk associated with temporary ATD may not
e so devastating as implied in previous reports. This informa-
ion could be helpful in situations with conflicting risks, such as
he unexpected need for major noncardiac surgery in patients
ith DES, but needs further confirmation because stent
hrombosis, even if rare, may have dire consequences.
tudy limitations and strengths. A total of 343 of 1,965
17.4%) patients were finally not followed up, in most cases
ecause they refused to participate. Although there were
11
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1
1
1
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Appendix), some kind of selection bias is possible. Partic-
ularly problematic are the 23 patients from this cohort who
died and in whom compliance with antiplatelet medication
could not be assessed. Stent thrombosis associated with ATD
cannot be ruled out as the ultimate cause of death. As
previously reported (10), none of these patients had undergone
invasive procedures or hospitalization for hemorrhagic compli-
cations before death, which are the most frequent circum-
stances we found associated with temporary ATD. However,
ATD on patient initiative is still possible. As additional
information, we could find out that none of these deaths
occurred during the first month after stenting and that at least
in 13 of them, the cause of death was not cardiac. Similarly,
105 of 1,622 patients (6.47%) were censored before completing
1 year of follow-up because of loss to follow-up, and thus their
final status could not be determined. However, most of these
follow-up losses occurred during the last follow-up period (i.e.,
from the 9th to the 12th month) when the risk associated with
ATD is likely lower.
A potential recall bias may exist concerning follow-up
information. However, most patients received a phone call
not later than 3 months after the previous one, and this
could minimize such bias. On the other hand, repeated calls
may have led patients to be more compliant with medica-
tion, so that in fact, the estimated rate of ATD could be
lower than it would have been in other contexts. Finally,
confounding bias is also possible.
Our study has additional strengths. We systematically eval-
uated antiplatelet medication resumption after discontinuation
with a structured survey, which is an uncommon practice in
studies assessing ATD, as is the distinction between both
drugs. We did a thorough quality control to ensure consecutive
inclusion and quality of data collection, as previously reported
(10). Finally, clinical records of readmitted patients were
centrally reviewed by the main investigator team.
Conclusions
ATD within the first year and beyond the first month after
DES is not exceptional and is usually temporary. Although
further knowledge about individual risk is desirable, our
results suggest that discontinuation for a few days (median:
7 days) of DAT after the first month of DES implantation
may be reasonably safe in terms of major cardiac events.
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